# Jaguar Health Completes Effectiveness Trial to Support FDA Approved Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
Canonical URL: https://biopharmsignal.com/news/JAGX/jaguar-health-completes-effectiveness-trial-to-support-fda-approved-crofelemer-for-treatment-of-chemotherapy-induced-diarrhea-cid-in-dogs
Ticker: JAGX
Company: Jaguar Health
Source: Jaguar Health
Published: 2026-04-08 12:30 EST
Original Source URL: https://jaguarhealth.gcs-web.com
## Summary

Topline results expected within a month and may complement positive results of a study of crofelemer for treatment of cancer therapy-induced diarrhea (CTD) in dogs receiving neratinib - a targeted tyrosine kinase inhibitor (TKI) SAN FRANCISCO, CA / ACCESS Newswire / April 8, 2026 / Jaguar Health,

## Article Body
Topline results expected within a month and may complement positive results of a study of crofelemer for treatment of cancer therapy-induced diarrhea (CTD) in dogs receiving neratinib - a targeted tyrosine kinase inhibitor (TKI) SAN FRANCISCO, CA / ACCESS Newswire / April 8, 2026 / Jaguar Health,
## Recent Company News
- 2026-05-28 14:00 EST — [Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Congenital Gastrointestinal Disorders](https://biopharmsignal.com/news/JAGX/jaguar-health-research-in-ethnobotanical-medicine-helps-advance-crofelemer-development-for-genetically-defined-rare-congenital-gastrointestinal-disorders) — Source: Jaguar Health
- 2026-05-27 13:00 EST — [Jaguar Health Compliant with Nasdaq Bid Price Rule](https://biopharmsignal.com/news/JAGX/jaguar-health-compliant-with-nasdaq-bid-price-rule) — Source: Jaguar Health
- 2026-05-20 20:40 EST — [Jaguar Health Reports First Quarter 2026 Financials](https://biopharmsignal.com/news/JAGX/jaguar-health-reports-first-quarter-2026-financials) — Source: Jaguar Health
- 2026-05-20 13:00 EST — [Jaguar Health to Hold Investor Webcast May 26 Regarding Q1 2026 Financials & Corporate Updates; Jaguar CEO Lisa Conte Presenting May 28 at Lytham Partners Spring 2026 Investor Conference](https://biopharmsignal.com/news/JAGX/jaguar-health-to-hold-investor-webcast-may-26-regarding-q1-2026-financials-and-corporate-updates-jaguar-ceo-lisa-conte-presenting-may-28-at-lytham-partners-spring-2026-investor-conference) — Source: Jaguar Health
- 2026-05-19 13:00 EST — [Jaguar Health Announces Active Treatment Only Continuation of Pivotal Multicenter Clinical Trial in Pediatric Patients with Microvillus Inclusion Disease (MVID) to Support a New Drug Application (NDA) for Liquid Oral Crofelemer](https://biopharmsignal.com/news/JAGX/jaguar-health-announces-active-treatment-only-continuation-of-pivotal-multicenter-clinical-trial-in-pediatric-patients-with-microvillus-inclusion-disease-mvid-to-support-a-new-drug-application-nda-for-liquid-oral-crofelemer) — Source: Jaguar Health
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)